Company Filing History:
Years Active: 2021-2024
Title: The Innovative Contributions of Sandra Giannini
Introduction
Sandra Giannini is a notable inventor based in Rixensart, Belgium. She has made significant contributions to the field of immunology through her innovative inventions. With a total of 5 patents to her name, Giannini's work focuses on engineered bacteriophages and their applications in immunogenic compositions.
Latest Patents
Among her latest patents, one invention discloses an engineered bacteriophage capable of binding to a commensal bacterium. This bacteriophage is designed to insert its genome polynucleotide into the commensal bacterium while being incapable of producing progeny or carrying out a lysogenic or lytic cycle. The engineered bacteriophage includes a genome polynucleotide with at least one gene encoding a heterologous antigen under the control of a promoter. Another significant patent reveals a recombinant bacteriophage that comprises a phage genome polynucleotide, which includes a gene encoding a heterologous antigen protein and a killing gene capable of eliminating a host bacterium. This recombinant bacteriophage is intended to prime a subject's immune response while simultaneously killing the bacterium it infects, providing a dual line of protection against infectious diseases.
Career Highlights
Sandra Giannini is currently associated with GlaxoSmithKline Biologicals SA, where she continues to advance her research and development efforts. Her work has been instrumental in the development of innovative solutions in the field of immunology.
Collaborations
Throughout her career, Giannini has collaborated with esteemed colleagues, including Julien Thierry Massaux and Christiane Marie-Paule Simone Jeanne Feron. These collaborations have further enriched her research and contributed to her success as an inventor.
Conclusion
Sandra Giannini's innovative contributions to immunology through her patents and collaborations highlight her significant role in advancing medical science. Her work continues to pave the way for new solutions in the fight against infectious diseases.